Nobles Medical Technologies II Unveils New Web Portal
New Portal Focuses On Serving Patients and Physicians
While Showcasing Current And Future Devices
Fountain Valley, California—September 6, 2016—Today Nobles Medical Technologies II (Nobles Med 2) launched a new web portal for both its U.S. and European markets, growing its ability to simultaneously dialogue with the world’s most forward-thinking cardiologists and cardiac surgeons—and their patients. A multi level platform that provides more content, including patient (http://www.noblesmed2.com/patients.html)and physician testimonials (http://www.noblesmed2.com/physicians.html), Instructional videos and real case videos using the NobleStitch™EL. The new web portal NoblesMed2.com was designed from the outset for patients searching for advanced surgical solutions, physicians looking to explore the latest innovations in their field, as well as providing advanced content for the media and investors, seeking the latest company news. With the growing demand for the NobleStitch™EL around the globe the site’s redesign is essential.
Professor Anthony Nobles, CEO of Nobles Med 2, commented, “Over the last year we have seen incredible momentum and with successful clinical outcomes across the globe. Over the next 12 months we will see that momentum increase as we add to our base of trained cardiologists; physicians have increasingly switched their standard of care from the traditional technique to the NobleStitch™ EL. We have seen increased public awareness of our technology with physicians who continue to publish and present their positive results using our NobleStitch™ EL. These publications demonstrate how the NobleStitch™ EL protects their patients from the long and short-term complications of ‘umbrella’-type implants; particularly with their experience using NobleStitch™EL in a diverse range of patients including younger patients suffering from stroke, severe migraine and chronic fatigue. This new portal is an imperative intuitive web interface that not only brings physicians and patients together to consider the remarkable benefits that NobleStitch™ EL technology can provide; it also brings their success stories to the world.”
Ben Brosch, Director of Nobles Med 2, commented, “In the internet and social media age, a quality web-site is essential. Nobles Med 2 is a state of the art medical device company inventing new technologies for structural heart. With the launch of the NobleStitch™ EL commercially around the world our focus now includes the marketing and sales effort that requires up to date information including publications, videos and interactive investor, clinical and patient information. It’s what a company in our position needs, and the time is right.”
About PFO Closure
A PFO is a relatively common heart defect characterized by an unsealed tunnel between the right and left atria of the heart. This defect has been known to be present in anywhere between 10%-25% of people. However, in a number of cases, it is benign.
The PFO is formed as a trace of the fetal circulation. When the chambers of a human heart begin to develop, a tunnel is made between the right and left atria, allowing blood to flow directly from the venous circulation to the arterial circulation, circumventing the non-functioning fetal lungs. Following birth, the pressure differential between the right and left atria changes with newly operational blood flow to the fully functioning lungs. Because of this, the tunnel eventually closes completely within the first few months.
However, in some patients, the foramen ovale fails to seal and stays "patent". In patients with a Patent Foramen Ovale (PFO), the tunnel can reopen under elevated atrial pressure, such as coughing, or straining.
A key issue with PFO is that it gives a pathway for blood clots to pass directly to the arterial circulation without being filtered out by the capillary bed of the lungs. A PFO can also let deoxygenated blood and certain chemicals to cross over to the arterial side. The presence of a PFO has been linked to a number of clinical issues, mainly stokes, migraines and chronic fatigue. Developments are being made to solidify the link between PFO and strokes or migraines, and to identify patients that would benefit from PFO closure.
For More About Atrial Septal Aneurysm, Visit http://www.medscape.com/viewarticle/704107_3
For more information, please contact shareholder representatives:
Dru Dobbs
P. +1 714 427 6348
F. +1 714 427 6343
About Nobles Medical Technologies II
Nobles Medical Technologies II, Inc. was founded with the intent of leveraging its technologies in the PFO and ASD-closure marketplace. The company does business under the name of Nobles Medical II (NMT II). Initial efforts of the company are focused on the innovative suture-based PFO closure system for closing the Patent Foramen Ovale (PFO), a tunnel between the right and left atria of the heart.
The NobleStitch™ is approved for PFO Closure and Cardiovascular suturing in the European Union. The NobleStitch™ EL is FDA cleared for vascular suturing in the United States. NobleStitch™ EL is distributed worldwide by HeartStitch®, Inc. (HeartStitch® is a registered trademark of HeartStitch, Inc.).
NobleStitch™ EL for PFO closure
Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.
For more on Nobles Medical Technologies II visit www.noblesmed2com.
Tags:
